TMPRSS2 and chronic pancreatitis: In this regard, TMPRSS2 serine protease inhibitor camostat mesylate has already been approved as a potential therapeutic in Japan for treating chronic pancreatitis and also has antiviral properties.25 Markus, H. et al. had performed intensive in vitro analysis, and the results showed that clinically proven camostat mesylate could hamper the viral entry of SARS-CoV-2 similarly to that of SARS COV by inhibiting the host cell serine protease TMPRSS2.